NASDAQ · Biotechnology

Enlivex Ltd. (ENLV) Stock

$0.25 -8.30% NASDAQ: ENLV Healthcare

Valuation

MetricValue
Price$0.25
Market Cap$4.28M
P/E Ratio0.03
P/B Ratio0.01
P/S Ratio0.00
EPS (TTM)$25.48
52-Week High$27.15
52-Week Low$0.25
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE279.88%
ROA83.82%
ROCE-0.42%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio193.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-19.0M$-26.0M$-29.0M$-16.0M$-15.0M
Net Profit$-14.0M$-31.0M$-29.0M$-15.0M$1.2B
EPS$-8.10$-34.65$-23.40$-10.95$382.20
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$95.0M$68.0M$37.0M$28.0M$2.3B
Total Liabilities$10.0M$11.0M$7.0M$4.0M$392.0M
Cash$11.0M$50.0M$1.0M$3.0M$2.0M
Borrowings$6.0M$5.0M$1.0M$1.0M$1.0M

Latest News

Enlivex Therapeutics Granted Patent in Australia for Allocetra to Treat Osteoarthritis MT Newswires · Jun 15, 2026 Enlivex advances Allocetra while expanding into prediction markets Proactive · May 11, 2026 Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress GlobeNewswire · Apr 23, 2026 H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook Insider Monkey · Apr 21, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-18.0M$-24.0M$-24.0M$-13.0M$-10.0M
Investing Cash Flow$-40.0M$54.0M$-26.0M$9.0M$-1.0M
Financing Cash Flow$8.0M$0$0$0$0
Net Cash Flow$5.0M$39.0M$-49.0M$3.0M$-1.0M
Free Cash Flow$-19.0M$-32.0M$-24.0M$-13.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.92
FCF Yield-248.11%
Quick Ratio119.39
Interest Coverage-15.46
Return 1Y-67.59%
Return 3Y-83.25%
Return 5Y-94.66%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Enlivex Ltd.

Enlivex Ltd. is led by CEO Oren Hershkovitz, employs 71 people, headquartered in IL, publicly traded since 2014.

Enlivex Ltd. (ENLV) stock trades at $0.25 with a market capitalization of $4.28M. The stock is valued at a price-to-earnings (P/E) ratio of 0.03, price-to-book of 0.01, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.25 and $27.15, and currently trades 99.1% below its 52-week high.

On profitability, Enlivex Ltd. generates a return on equity (ROE) of 279.88% — well above the market average, a sign of a high-quality business, return on capital employed of -0.42%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides